This is the second installment in my write-up of the proposed Oregon psilocybin program rules. I’m jumping in midstream from where I left off yesterday in Part 1. Similar to that installment, I will highlight the major areas, and skip or skim less prominent stuff. This batch of proposed rules is 65 pages, after all.
The Oregon Health Authority (OHA) released the rest of its draft psilocybin rules as predicted a few weeks back. We’ve had a minute to look at them. This post and the next few will cover some of the high points. In general, OHA did a good job implementing the Oregon Psilocybin Advisory Board’s (“Board”) recommendations
This will be one of the most important weeks for Oregon psilocybin to date, at least from a news and public information perspective. This is because we expect the Oregon Health Authority (OHA) to publish all remaining proposed administrative rules for the Oregon psilocybin program. The forthcoming rules should cover everything outlined in Measure 109
In 2023, Oregon will have a regulated psilocybin market. Colorado voters will have a chance to vote on something similar this fall (although Initiative 58 would not take effect until 2024). Other than that, not a single other state has any form of psychedelic regulation in the works. Last week, an attempt to simply decriminalize
Jamaica is establishing itself as a global psilocybin leader. It surprises many people to learn that psilocybin has never been prohibited in the Caribbean nation and is not one of the controlled substances listed in Jamaica’s Dangerous Drugs Act. Over the past few years, we’ve fielded a number of inquiries in and around prospective and
Welcome to the fifth installment in this series surveying business and regulatory issues in the Oregon psilocybin program. Today I will cover intellectual property considerations for Oregon psilocybin businesses. My law firm has written and presented many hundreds of times on intellectual property and controlled substances over the years. Mostly, this material focused on the
A recently published letter (“Letter”) indicates that the Biden administration is preparing for the approval of psychedelic drugs and MDMA to treat mental illness and PTSD. This type of federal agency correspondence would have been unimaginable five or six years ago. Things are changing fast! There are well-known potential health benefits of MDMA and psychedelics
Since January 1, 2021, the Oregon Health Authority (OHA) has engaged in a two-year development phase, creating regulations based on Ballot Measure 109. There are five subcommittees covering different aspects of the emerging psilocybin industry including research, health equity, manufacturing, training, and licensing. In this post, we will cover the most recent Research Subcommittee meeting
The Oregon Psilocybin Advisory Board (OPAB) was established by Measure 109 and is responsible for making recommendations to the Oregon Health Authority (OHA) for psilocybin services in Oregon. OPAB has met monthly since March of 2021, and the last monthly meeting was set for June 22, 2022. After that, OPAB will meet every two months. In a
In November 2020, Oregon voters passed Measure 109, which directs the Oregon Health Authority (OHA) to license and regulate the manufacture, delivery, sale, and administration of psilocybin. Licensing is set to kick off in early 2023. Things remain on track. We’ve written a lot about Measure 109 here on the Psychedelics Law Blog, including: 1)
